Ludovic Lacroix

26PUBLICATIONS
292CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Cancer geneticsPredictive and prognostic markersMolecular targetsLiquid biopsies
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (26)

|Jul 13, 2026
Role of ctDNA Tumor Fraction in Selecting Immunotherapy Based Regimens in Advanced Non-small Cell Lung Cancer.

|Feb 06, 2026
Genetic variant interpretation in tumours in the French national ring trials Gen&Tiss - main criteria of improvement.

Medina Kalimulaeva, Leen Van Langenhoven, Karen Leroy

|Jan 27, 2026
Phase I/II Study of the PARP Inhibitor Olaparib and Irinotecan in Children and Young Adults with Recurrent/Refractory Malignancies: Arm D of the AcSé-ESMART Trial.

Susanne A Gatz, Pablo Berlanga, Gwénaël Le Teuff

|Sep 10, 2025
Molecular analysis of lung adenocarcinomas from the SAFIR02-Lung cohort reveals new metastasis-associated copy-number alterations including frequent mutant-specific KRAS-allelic imbalance and identifies CDKN2A homozygous deletions as an independent biomarker of poor prognosis.

Abderaouf Hamza, Pierre Gestraud, Maryam Karimi

|Oct 09, 2024
CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors.

Ferdinandos Skoulidis, Haniel A Araujo, Minh Truong Do

|Oct 07, 2024
Tumor fraction-based prognostic tool for cancer patients referred to early phase clinical trials.

Arnaud Bayle, Laila Belcaid, Sophie Cousin

Pageof 5

Frequent Collaborators

12 joint publications

Benjamin Besse

7 joint publications

Fabrice Andre

7 joint publications

Luc Friboulet

6 joint publications

Damien Vasseur